Advancing the Diagnostic-to-Treatment Continuum in Cancer Care –
Irvine

Advancing Hematologic Care Through Collaboration and Clinical Insight

Irvine, California, is home to a rapidly growing hub of clinical innovation and translational research. This program is presented in partnership with City of Hope, Orange County, bringing together hematologists, oncologists, pathologists, and healthcare professionals to explore evolving treatment strategies and real-world approaches to patient care.

The program will be co-chaired by Tanya Siddiqi, MD, Medical Director of Lymphoma and IEC Programs at City of Hope Orange County and Professor in the Department of Hematology and Hematopoietic Cell Transplantation. Dr. Siddiqi is a nationally recognized leader in lymphoid malignancies and cellular therapies, with extensive experience in clinical trials and the development of novel treatment approaches in CLL and lymphoma.

Joining her as co-chair is Lisa Lee, MD, Associate Clinical Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope. Dr. Lee brings a strong clinical focus on hematologic malignancies and multidisciplinary care, with expertise in translating emerging therapies into practical treatment strategies.

This clinically focused program highlights contemporary management strategies across hematologic malignancies, with an emphasis on practical, real-world decision-making and evolving treatment paradigms. Through expert-led sessions and interactive panel discussions, the meeting will explore advances in myeloid and lymphoid malignancies, cellular therapies including CAR-T and bispecific antibodies, and emerging approaches in multiple myeloma, amyloidosis, and monoclonal gammopathies.

Participants will gain actionable insights into treatment sequencing, toxicity management, and patient selection, while engaging in multidisciplinary dialogue that supports informed clinical decision-making. Continuing education credits (CME/CE and MOC) are planned for this activity.